These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

44 related articles for article (PubMed ID: 11558697)

  • 1. Patent Portfolios Protecting 10 Top-Selling Prescription Drugs.
    Horrow C; Gabriele SME; Tu SS; Sarpatwari A; Kesselheim AS
    JAMA Intern Med; 2024 Jul; 184(7):810-817. PubMed ID: 38739386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limiting "evergreening" for a better balance of drug innovation incentives.
    Stanbrook MB
    CMAJ; 2013 Aug; 185(11):939. PubMed ID: 23877665
    [No Abstract]   [Full Text] [Related]  

  • 3. Ancillary Product Patents to Extend Biologic Patent Life.
    Goode R; Feldman WB; Tu SS
    JAMA; 2023 Dec; 330(21):2117-2119. PubMed ID: 37955940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of market exclusivity on drug availability and medical innovations.
    Glover GJ
    AAPS J; 2007 Aug; 9(3):E312-6. PubMed ID: 17915833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inequitable Conduct and Invalidation of Patents Related to Food and Drug Administration-Regulated Products.
    Tu SS; Leadmon C; Daval CJR; Kesselheim AS
    JAMA; 2023 Dec; 330(21):2119-2121. PubMed ID: 37955942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Developing products for personalized medicine: NIH Research Tools Policy applications.
    Gupta R; Kim J; Spiegel J; Ferguson SM
    Per Med; 2004 Dec; 1(1):115-124. PubMed ID: 19960108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patent lifecycle management strategies in open innovation projects.
    Lee Y; Fong EA
    Drug Discov Today; 2020 Oct; 25(10):1782-1785. PubMed ID: 32592662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secondary patents in the pharmaceutical industry: missing the wood for the trees?
    Kiran S; Kulkarni M
    Expert Opin Ther Pat; 2018 Mar; 28(3):241-250. PubMed ID: 29298119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Realizing two-tiered innovation policy through drug regulation.
    Ridgway WE
    Stanford Law Rev; 2006 Feb; 58(4):1221-50. PubMed ID: 16685807
    [No Abstract]   [Full Text] [Related]  

  • 10. The Impact of Off-Patent Drug Acquisitions on Prices.
    Gupta R; Henkel A; Forman HP; Ross JS
    J Gen Intern Med; 2018 Jul; 33(7):1007-1009. PubMed ID: 29687433
    [No Abstract]   [Full Text] [Related]  

  • 11. Reanalyzing reverse payment settlements: a solution to the patentee's dilemma.
    Wang Z
    Cornell Law Rev; 2014 Jul; 99(5):1227-58. PubMed ID: 25112001
    [No Abstract]   [Full Text] [Related]  

  • 12. Ownership of knowledge--the role of patents in pharmaceutical R&D.
    Correa CM
    Bull World Health Organ; 2004 Oct; 82(10):784-7; discussion 787-90. PubMed ID: 15643801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
    McCabe AR
    Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844
    [No Abstract]   [Full Text] [Related]  

  • 14. The shifting functional balance of patents and drug regulation.
    Eisenberg RS
    Health Aff (Millwood); 2001; 20(5):119-35. PubMed ID: 11558697
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.